Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

News Daily News

FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF

July 14, 2025

FDA Grants MACE Reduction Indication for Semaglutide

News Daily News

FDA Grants MACE Reduction Indication for Semaglutide

March 08, 2024

FDA Approves Paradise Renal Denervation System: What Comes Next?

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

November 08, 2023

FDA Approves Colchicine for Decreasing CV Events

News Daily News

FDA Approves Colchicine for Decreasing CV Events

June 20, 2023

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

News Daily News

FDA Grants First HF Indication for IV Iron to Ferric Carboxymaltose

June 05, 2023

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

News Daily News

Sotagliflozin Gets FDA Approval in HF Across EF Spectrum

May 30, 2023

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

News Daily News

FDA Extends Dapagliflozin Indication Across LVEF Spectrum

May 09, 2023

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

FDA Approves Dapagliflozin for CKD Patients

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

FDA Grants Cardiac MR Indication for Gadavist Contrast Injection

News Daily News

FDA Grants Cardiac MR Indication for Gadavist Contrast Injection

July 16, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.